Overview

More than half a million people worldwide are now sustained by renal replacement therapy, mainly haemodialysis at a cost exceeding 30 billion dollars per year. Each case of ESRD that is delayed or prevented saves funds that may be applied to other aspects of health care. This work provides a summary of work in progress directed toward renoprotection and of ultimate interdiction of ESRD. Suitable for researchers and clinicians, Dr. Morrell Michael Avram has collected and commented on promising initiatives likely to enter everyday practice.

Full Product Details

Author:   M.M. Avram
Publisher:   Springer-Verlag New York Inc.
Imprint:   Springer-Verlag New York Inc.
Edition:   2002 ed.
Dimensions:   Width: 21.00cm , Height: 1.10cm , Length: 27.90cm
Weight:   0.504kg
ISBN:  

9781402009952

ISBN 10:   140200995
Pages:   134
Publication Date:   31 October 2002
Audience:   College/higher education ,  Professional and scholarly ,  Undergraduate ,  Postgraduate, Research & Scholarly
Format:   Hardback
Publisher's Status:   Active
Availability:   Awaiting stock  
The supplier is currently out of stock of this item. It will be ordered for you and placed on backorder. Once it does come back in stock, we will ship it out for you.

Table of Contents

1. How to Achieve Maximal Renoprotection in Non-Diabetic Chronic Renal Disease.- 2. Anemia of Chronic Kidney Disease and its Management with Recombinant Human Erythropoietin and Darbepoetin Alfa.- 3. Cardiovascular Disease in Patients with Chronic Kidney Disease: The Causes and Effects.- 4. Metabolic Pathogenesis of Cardio-Renal Disease.- 5. Oxidative Stress and Inflammation in Hemodialysis Patients.- 6. Prognostic Value of Enrollment Parathyroid Hormone in Hemodialysis and Peritoneal Dialysis Patients for Survival. A 14 years Follow-up.- 7. Prealbumin as an Important Predictor for Survival and Nutritional Status in Hemodialysis and Peritoneal Dialysis Patients.- 8. How to Attain Optimal Antiproteinuric Dose of Losartan in Non-Diabetic Patients with Nephrotic Range Proteinuria.- 9. Hypoalbuminemia in the Patient with Renal Disease: Its Causes and Consequences.- 10. Kidney Disease and Mechanisms that Cause Loss of Muscle Mass.- 11. Role of Plasma Homocysteine and Plasminogen Activator Inhibitor-1 in the Progression of Diabetic Nephropathy.- 12. Effects of Erythropoietin (EPO) and Aminoguanidine (AG) on Deformability (df) in Diabetic Azotemic and Uremic Patients.- 13. Characterization of the PKD1 Gene Product, Polycystin-1.- 14. Nutrition and Blood Pressure.- 15. How to Minimize Bone Disease in Renal Failure.

Reviews

Author Information

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions